While previous NAD+ restoration strategies have primarily targeted biosynthetic pathways [64,65], our findings demonstrate that co-targeting degradation (e.g., CD38 inhibition) yields comparable benefits, thereby expanding the therapeutic landscape for age- and obesity-associated metabolic disorders. This evidence concerns the gene CD38 and obesity disorder.